| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Pyridin-4-ol does not have a defined biological target as a therapeutic agent. Its primary applications are as a chemical intermediate and a research reagent. The compound may be used in the synthesis of various pharmaceuticals, including diuretics, where its biological activity would be determined by the final drug molecule. The pyridone scaffold is found in numerous bioactive compounds, but the parent compound itself is not characterized for direct pharmacological effects.
|
|---|---|
| ln Vitro |
Specific in vitro activity data for Pyridin-4-ol as a pharmacological agent are not documented in the literature. It is primarily used as a chemical intermediate and a research reagent. The compound's derivatives, which contain the pyridone or hydroxypyridine moiety, may exhibit various biological activities depending on their specific structures. However, the parent compound itself is not characterized for direct biological effects such as enzyme inhibition or receptor modulation.
|
| ln Vivo |
Pyridin-4-ol is not used for in vivo pharmacological activity assessment as a drug compound. Its primary applications are as a chemical intermediate and a research reagent. The compound is not intended to be administered to animals for pharmacological studies. Its derivatives, which are synthesized from this building block, may be evaluated in vivo depending on their therapeutic targets.
|
| Enzyme Assay |
As a chemical intermediate, Pyridin-4-ol is not typically used in enzyme/receptor binding assays. Its role is in the synthesis of compounds that may be evaluated in such assays. When used in research, it serves as a starting material for the preparation of pyridine and pyridone derivatives. Standard synthetic chemistry protocols are employed for its use, rather than biochemical assay procedures.
|
| Cell Assay |
Pyridin-4-ol is not used in cell-based assays as a test compound. Its primary application is as a chemical intermediate for the synthesis of more complex molecules. The compound's derivatives, which contain the pyridone or hydroxypyridine moiety, may be evaluated in cell-based assays for various biological activities. However, the parent compound itself is not characterized for direct cellular effects.
|
| Animal Protocol |
Pyridin-4-ol is not used in animal studies as a pharmacological agent. Its primary application is as a chemical intermediate in organic synthesis. The compound is not intended to be administered to animals for efficacy or safety evaluations. Its derivatives, which are synthesized from this building block, may be evaluated in animal models depending on their therapeutic targets.
|
| ADME/Pharmacokinetics |
Pyridin-4-ol has a molecular weight of 95.10 g/mol and a molecular formula of C₅H₅NO. It exists in tautomeric equilibrium with 4-pyridone. The compound is a solid at room temperature and is soluble in water and organic solvents. It is used as a biochemical reagent and as a building block for pharmaceutical synthesis. The compound is typically stored under standard laboratory conditions.
|
| Toxicity/Toxicokinetics |
Pyridin-4-ol is intended for research use only and is not approved for human therapeutic applications. As a chemical intermediate, comprehensive toxicological data are not available in the publicly accessible literature. Standard safety precautions should be observed when handling this compound, including the use of appropriate personal protective equipment. The compound should be handled in well-ventilated areas with proper waste disposal procedures.
|
| Additional Infomation |
4-Pyridinone is the simplest member of the pyridine-4-one class, namely 1,4-dihydropyridine, in which the hydrogen atom at the 4-position is replaced by a carbonyl group. It is a tautomer of 4-hydroxypyridine.
Pyridin-4-ol (4-Hydroxypyridine) (CAS#: 626-64-2) has a molecular formula of C₅H₅NO and a molecular weight of 95.10 g/mol. It exists in tautomeric equilibrium with 4-pyridone. The compound is used as a biochemical reagent and as a building block for the synthesis of diuretic drugs and other pharmaceutical intermediates. This compound is not a drug and has not undergone clinical trials. |
| Molecular Formula |
C5H5NO
|
|---|---|
| Molecular Weight |
95.10
|
| Exact Mass |
95.037
|
| CAS # |
626-64-2
|
| Related CAS # |
Pyridin-4-ol-d5;45503-33-1
|
| PubChem CID |
12290
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
380.6±0.0 °C at 760 mmHg
|
| Melting Point |
150-151 °C(lit.)
|
| Flash Point |
182.3±20.4 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.560
|
| LogP |
-1.3
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
7
|
| Complexity |
121
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1C([H])=C([H])N([H])C([H])=C1[H]
|
| InChi Key |
GCNTZFIIOFTKIY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H5NO/c7-5-1-3-6-4-2-5/h1-4H,(H,6,7)
|
| Chemical Name |
1H-pyridin-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 10.5152 mL | 52.5762 mL | 105.1525 mL | |
| 5 mM | 2.1030 mL | 10.5152 mL | 21.0305 mL | |
| 10 mM | 1.0515 mL | 5.2576 mL | 10.5152 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
